PubMed Central
The International Journal of Neuropsychopharmacology, 2024 · Cited by 10 papers · doi:10.1093/ijnp/pyae052
Read the original →
Lumateperone is a novel approved APD by the FDA for treating adults with schizophrenia or bipolar I and II depression, either as monotherapy or in conjunction with lithium or valproate.
Canadian Network for Mood and Anxiety Treatments ( CANMAT ) and International Society for Bipolar Disorders ( ISBD ) 2018 guidelines for the management of patients with bipolar disorder
Bipolar Disorders · Mar 1, 2018 High trust
Cariprazine for Treating Schizophrenia, Mania, Bipolar Depression, and Unipolar Depression: A Review of Its Efficacy - PMC
PubMed Central High trust
Improving Treatment Adherence in Bipolar Disorder: A Review of Current Psychosocial Treatment Efficacy and Recommendations for Future Treatment Development - PMC
Sleep loss as a trigger of mood episodes in bipolar disorder: individual differences based on diagnostic subtype and gender - PMC
Outcome of single manic episode in bipolar I disorder: a six-month follow-up after hospitalization - PMC
Cognitive impairment in manic bipolar patients: important, understated, significant aspects - PMC